105 results about "Viral load" patented technology

Waning immunity induced by first-generation Spike-alone-based COVID-19 has failed to prevent immune escape by many variants of concern (VOCs) that emerged from 2020 to 2024, resulting in a prolonged COVID-19 pandemic. Thus, a next-generation Coronavirus (CoV) vaccine incorporating highly conserved non-Spike SARS-CoV-2 antigens is described herein. Conserved non-Spike T cell antigens in combination with a Spike antigen encapsulated in lipid nanoparticles: (i) Induced high frequencies of lung-resident antigen-specific CXCR5+CD4+ T follicular helper cells, GzmB+CD4+ and GzmB+CD8+ cytotoxic T cells, and CD69+IFN-γ+TNFα+CD4+ and CD69+IFN-γ+TNFα+CD8+ effector T cells; and (ii) Reduced viral load and COVID-19-like symptoms caused by various VOCs. The combined antigen / LNP-based pan-CoV vaccine could be rapidly adapted for clinical use to confer broader cross-protective immunity against emerging highly mutated and pathogenic VOCs.

This invention provides a highly pathogenic feline calicivirus strain, its vaccine, and its applications. The highly pathogenic feline calicivirus was isolated from pathogenic material and identified as a highly pathogenic strain, named FCV CC475, with its cDNA sequence shown in SEQ ID NO.1. This strain exhibits strong pathogenicity, causing infected animals to develop symptoms such as fever, paw pad ulcers, and dehydration by day 3 post-infection; the viral load after 5 generations is 10. 9.80 TCID 50 / ml. This strain produces high antibody titers after immunization of cats and rabbits, demonstrating good immunogenicity. Therefore, this highly pathogenic feline calicivirus has broad application prospects in the preparation of feline calicivirus infection vaccines, diagnostic reagents, or therapeutic drugs.

The invention discloses a method, a system, equipment and a medium for detecting an HPV (human papilloma virus) DNA (deoxyribonucleic acid) integration event, and relates to the technical field of gene detection. According to the method, HPV types and virus loads (Ct values) pre-screened by qPCR are used as natural identifiers to guide grouping and mixing of samples, and HPV integrated event detection and sample tracing are synchronously realized through single sequencing. Clinical verification shows that compared with qPCR, the comprehensive sensitivity reaches 97.1%, and the cost is reduced by 60%. And a built-in targeted retest mechanism improves the reliability of a detection result. The invention provides a novel, traceable, economical and feasible solution, is used for high-throughput HPV-host genome integration feature analysis, balances cost, expandability and clinical accuracy, and provides a high-throughput and low-cost solution for HPV-related cancer screening.

The present inventors have conducted intensive studies on an antibody which controls HIV in an administration group with a high probability over a long period of time with one or several times of single-agent administration. As a result, the present inventors have surprisingly found that, when an SW-1C10 antibody, which is obtained by producing an antibody gene reported as 1C10 in silkworms, is singly administered only a few times, the viral load in the blood is suppressed to the detection limit or lower at an early stage in all of individuals to which the antibody has been administered, and moreover, the viral RNA load in the blood is maintained at the detection limit or lower for a long time of 12 weeks.

The invention provides oral streptococcus ZRSOR-5 as well as a related product, a method and application thereof. The preservation number of the streptococcus oral cavity ZRSOR-5 provided by the invention in the Guangdong Microbial Culture Collection Center is GDMCC No: 65352, and the preservation number of the streptococcus oral cavity ZRSOR-5 provided by the invention is CGMCC No: 65352. Experiments prove that the SOR preparation is prepared by diluting the SOR preparation with normal saline and inhaling the SOR preparation into mice in advance, so that the survival rate of influenza virus infected mice can be remarkably increased, and lung inflammation and virus load can be reduced. When the ZRSOR-5 preparation provided by the invention is used in advance, pneumonia caused by influenza viruses can be resisted.

The present application belongs to the field of veterinary medicine, and specifically discloses a traditional Chinese medicine composition for preventing and treating chicken infectious bronchitis, a preparation method and application thereof. The traditional Chinese medicine composition is composed of the following raw materials in parts by weight: Ephedra 12 parts, apricot kernel 12 parts, licorice 9 parts, coix seed 30 parts, forsythia 12 parts, honeysuckle 20 parts, white eupatorium 12 parts, smilax 20 parts, and purple violet 6 parts. The composition can be used for preventing and treating artificially infected IBV chicks, and can significantly improve the survival rate of chicks, alleviate the decrease in body weight growth caused by IBV, relieve clinical symptoms, reduce the viral load in trachea and kidney tissues, reduce organ pathological damage, and promote the recovery of the body. The traditional Chinese medicine composition for preventing and treating chicken infectious bronchitis is easy to obtain, rich in resources, low in cost, safe, non-toxic and non-residual, and the preparation method is simple and suitable for large-scale production.

This invention, entitled "A Method and Application for Target Gene Quantification in qPCR Using a Quantitative Internal Standard and a Comprehensive Correction Coefficient," belongs to the field of nucleic acid detection technology. The technical problem it addresses is that existing qPCR techniques require the establishment of a standard curve using a reference sample of known concentration, increasing reagent costs and experimental complexity, and resulting in poor reproducibility. The key technical solution is to provide a method for quantitative viral load qPCR analysis of a single sample. Specifically, it provides an internal standard with a known copy number, i.e., a quantitative internal standard, and establishes a correction method. Through a systematic error compensation mechanism, it achieves accurate quantification of the target gene. This method ensures both accuracy and reproducibility while simplifying detection design in clinical applications.

The application discloses a kind of avian influenza and avian infectious bronchitis two-union recombinant subunit vaccine and its preparation method and application.The recombinant protein is by replacing the head domain of AIV HA protein with the RBD domain of IBV S protein, while adding GCN4, Trimer-tag trimer tag in sequence, the recombinant protein obtained, the recombinant protein is expressed in vitro using insect cells and prepared into subunit vaccine.The vaccine prepared by the application can produce high-level neutralizing antibodies against homologous and heterologous H9N2 subtype avian influenza virus after immunizing chicken population, while significantly reducing the virus discharge level and the histopathological changes caused, and can also induce high-level specific antibodies and neutralizing antibodies against QX subtype avian infectious bronchitis virus, effectively inhibit discharge, viral load, and reduce tissue lesions.The application does not depend on chicken embryo, and has low production cost and short cycle, and can simultaneously prevent avian influenza and avian infectious bronchitis.

The invention relates to an mRNA (messenger Ribonucleic Acid) vaccine aiming at a fever with thrombocytopenia syndrome virus (SFTSV) and application of the mRNA vaccine. According to the vaccine, Gn and Gc glycoproteins are co-expressed in vivo, and four optimized mutations are introduced at key sites: N33Q, N63Q and K288R of the Gn protein and S962A of the Gc protein. The mutation can remove glycosylation, enhance protein conformational stability and reduce Gc-mediated membrane fusion activity, thereby improving the immunogenicity and safety of the antigen. The mRNA vaccine provided by the invention can induce a neutralizing antibody with a higher level; in a mouse challenge experiment, the vaccine shows higher survival rate and lower virus load, and has an excellent protection effect. Therefore, the mRNA vaccine disclosed by the invention has a wide application prospect in the aspect of preventing the severe fever with thrombocytopenia syndrome virus.

Peptides generating antibodies to human immunodeficiency virus (HIV) post-infection were identified. Higher antibody reactivity to these peptides was associated, with lower viral load post-infection.

The invention belongs to the technical field of biology, and particularly relates to a construction method of a respiratory syncytial virus infected mouse model. Disodium clodronate liposome with the concentration of 4ng / mL is injected into the lateral ventricle of the mouse through stereotactic positioning of the brain. 48h after injection, mouse brain tissues are taken to detect the activation state of microglial cells through immunofluorescence and WB, after it is confirmed that the microglial cells are inhibited, RSV (virus titer: 2.8 * 10 < 6 > PFU) nasal drop infection experiments are carried out on the mouse, and after the 5th day after virus infection, the mouse is infected by the RSV (virus titer: 2.8 * 10 < 6 > PFU) nasal drop infection experiments. Likewise, mouse brain tissue is taken for virus load detection, and neuropathological changes of the mouse brain tissue are observed through HE staining, immunofluorescence and TUNEL staining, so that the method can be used for constructing a research model of RSV-related nervous system diseases.

A solution has been discovered that provides a more effective Coronavirus vaccine. The solution is an mRNA vaccine encoding a SARS-CoV-2 nucleoprotein (N) (mRNA-N) in combination with an mRNA vaccine encoding SARS-CoV-2 spike protein(S) (mRNA-S). Chemically modified mRNA-N (pseudouridine) and / or chemically modified mRNA-S (pseudouridine) can be synthesized and packaged in lipid nanoparticles (LNP). In mouse and hamster models, it was shown that mRNA-N alone is immunogenic and can significantly diminish viral loads in the mouse lung after prime-boost intramuscular immunization. In addition, the combinatorial mRNA-N / mRNA-S vaccination induces substantially stronger protection against SARS-CoV-2 than vaccination with mRNA-S alone.

The invention provides an application and a method of an RSAD2 agonist glycopyrronium in resisting RSV infection. The method comprises the following steps: S1, virtual screening and molecular docking; s1.1, performing virtual screening and molecular docking; s1.2, carrying out molecular dynamics simulation; s2, cell culture and RSV infection; s3, performing RT-qPCR detection on the expression of the RSAD2 and the virus load of the RSV; s4, performing Westernblot analysis on the influence of a small molecule compound on the expression of the RSAD2; s5, CCK8 is used for detecting the toxicity of the compound to Beaas-2b cells; s6, carrying out indirect immunofluorescence detection on a fluorescence signal of the RSV; s7, animal model establishment; s8, carrying out HE dyeing; s9, carrying out enzyme-linked immunosorbent assay (ELISA); and S10, statistical analysis. According to the present invention, the small molecule agonist targeting the host immune factor RSAD2 is screened, the endogenous antiviral factor is activated from the host perspective, the drug resistance problem caused by direct virus targeting is avoided, the RSAD2 is adopted as the host natural antiviral molecule, the activation strategy has good targeting property and good safety, and the efficient anti-RSV effect under the low toxic-side effect is achieved.

The application discloses a kind of multi-stage progressive exclusion and verification robust sparse sample mixed detection method and system, belong to popular disease early infection screening technical field.The method includes: according to the mixed detection parameter of screening scene setting;Subsequently enter multi-stage detection process, according to the current sample quantity to be detected in each stage, dynamically adjust mixed pool scale and detection times, and according to the detection result, sample is continuously classified and screened, and gradually exclude definite negative sample, while directly lock part of definite positive sample by analyzing the remaining sample in positive pool;Finally, the remaining sample is detected separately, and the identification of all positive samples is completed.The present application effectively copes with the uncertainty in actual detection through the robust multi-stage progressive design and dynamic adjustment mechanism, while ensuring the detection efficiency, significantly improves the detection rate of low viral load samples, has the characteristics of strong implementability and wide adaptability, and is suitable for large-scale sparse sample detection scene.

The invention provides an oral antibacterial film-forming spray and a preparation method thereof. The preparation method of the oral antibacterial film-forming spray comprises the following steps: S100, uniformly mixing and stirring xylitol, glycerol, butanediol and medical purified water, heating and dissolving to obtain a solution A; s200, uniformly mixing and stirring an antibacterial component and medical purified water, heating and dissolving to obtain a solution B; s300, uniformly mixing and stirring the film-forming component and the remaining medical purified water, dissolving, freezing, and unfreezing to obtain a solution C; and S400, uniformly mixing and stirring the solution A and the solution B, adding the solution C, and uniformly mixing to obtain the oral antibacterial film-forming spray. According to the oral cavity film-forming spray, a protective film with a bacteriostatic effect is formed, the growth of harmful bacteria can be inhibited, the virus load can be reduced, and the added film-forming component is matched with the prebiotics component, so that the growth of beneficial flora in the oral cavity can be promoted; meanwhile, the preparation method is simple in synthesis and low in production cost.

The application discloses a single-tube quantitative detection HCV viral load real-time fluorescent quantitative PCR kit and belongs to the technical field of molecular biological detection. The kit comprises a pair of primers and a probe combination, the primer and the probe combination comprise a primer pair and a probe for detecting a target gene and a probe for detecting an internal standard. The kit can detect HCV 1-6 common types in clinic, covers all types, can stably detect a viral load of 10 IU / mL, has high detection sensitivity and good repeatability, does not need additional quantitative reference product to construct a calibration curve, simplifies operation, improves the utilization rate of reagents, and avoids invalid results and repeated detection caused by the failure of calibration curve construction.

Disclosed are an rBJ-VVL plasmid, a mutant strain of NADC34-like PRRSV-2 and a preparation method therefor and application thereof. Further disclosed is an NADC34-like PRRSV-2-specific vaccine. In the present disclosure, a modified strain rBJ-VVL with tropism for Marc-145 cells is obtained by precisely mutating an amino acid at positions 91 / 97 / 98 of GP2a; the modified virus constructed in the present disclosure can be propagated in Marc-145 cells, cause cytopathic effects and form plaques when inoculated into Marc-145 cells for serial passage; the resulting Marc-145 cell-passaged viruses have an extremely viral load, and a large number of new progeny viruses can be obtained in a short time; and the Marc-145-adapative modified strain cultured in the present disclosure is used to create a first NADC34-like PRRSV-2-specific vaccine.

The present disclosure relates to a kit and a method for purifying retrovirus, which comprises a reagent combination for purifying retrovirus, comprising a first eluent, a second eluent, an elution liquid and a polyanion compound. By using the purification chromatography combination and method of the present disclosure, the viral load can be increased, the chromatography recovery rate of retrovirus is increased by 2-3 times, reaching 80% and above; at the same time, the impurity level in the virus elution liquid is significantly reduced, such as the residual amount of HCP, which can be reduced by 2-3 times; the eluted retrovirus elution liquid can be stored for 24 hours without losing the infection activity under high salt conditions without adding other special protection reagents; after elution, the next step of ultrafiltration dialysis can be directly carried out without the step of dilution and then concentration, effectively simplifying the operation steps and shortening the processing time.

The application relates to the technical field of aquatic virus prevention and treatment, and particularly discloses application of YTX in preparation of a medicine for preventing and treating SCRV infection. The application verifies the prevention and treatment effects of YTX on SCRV infection through fish body level experiments. The experimental results show that, in a safe concentration range, YTX can significantly improve the survival rate of fish after SCRV infection by being administered through soaking or injection, the relative protection rate is more than 85%; the virus load in target organs such as kidneys and spleens is significantly reduced, the virus copy number is reduced by 2-3 logarithmic levels; and the pathological damage such as tissue necrosis and inflammatory infiltration caused by the virus is effectively reduced. The application verifies the anti-SCRV effect of YTX at the fish body level for the first time, provides key data support for development and application of YTX as a new aquatic antiviral preparation, and has important industrial application value.

The invention discloses an application of a UFMylation regulator in preparation of a medicine for resisting HIV (Human Immunodeficiency Virus) infection. According to the application disclosed by the invention, through in-vivo and in-vitro pharmacodynamic experiments, the inhibition effect of a UFMylation regulator, namely a UFSP2 inhibitor Compond-8, on an HIV (Human Immunodeficiency Virus) is evaluated. Experimental results show that the Compound 8 can significantly inhibit the replication of MT-4 cells, primary CD4 + T cells and HIV viruses in mice, can still maintain low virus load after drug withdrawal, has no obvious influence on the proliferation of normal cells and the weight of mice, and has a good anti-HIV infection effect and high safety. The invention reveals that the Compound 8 effectively inhibits HIV-1 replication for the first time, prompts that the Compound 8 can be used as a candidate drug of an HIV-1 treatment drug, provides a new treatment strategy for AIDS, and has a wide application prospect in the field of HIV infection resistance.

This invention discloses the application of dapoxetine (FK866) in the preparation of drugs inhibiting influenza viruses, belonging to the fields of biotechnology and pharmaceutical technology. This invention is the first to discover that the nicotinamide phosphoribosyltransferase (NAMPT) inhibitor FK866 can inhibit influenza A virus at the cellular level, and FK866 also exhibits broad-spectrum antiviral activity against different subtypes of influenza virus. FK866 affects the expression of viral mRNA, cRNA, and vRNA. Simultaneously, it was found that FK866 can also inhibit influenza virus infection in vivo, protecting 50% of mice from death 14 days after infection, and reducing viral load and pathological damage in lung tissue.

The invention discloses a monoclonal antibody MPXV-mAb 975 and an application of the monoclonal antibody MPXV-mAb 981 in preparation of a medicine for preventing and treating a monkey pox virus. According to the invention, an established plaque phenotype experiment is utilized to evaluate the neutralizing activity of the two antibodies to the VACV, and the result shows that the two monoclonal antibodies can inhibit the propagation of the VACV between cells; effects of ADCC and ADCP mediated by the two antibodies are detected, and through a reporter gene experiment, the two antibodies show potential ADCC and ADCP activity; animal model data shows that both the two antibodies can protect CAST / EiJ mice and rhesus monkeys, monkey pox virus loads in different tissues and organs of the mice are remarkably reduced, and the number of acnes on the skin of the rhesus monkeys is reduced. The invention proves that the two monoclonal antibodies have in-vivo and in-vitro protection effects, can be used as effective prevention and treatment medicines for monkey pox virus infection, and provide candidate antibody preparations for clinical treatment of monkey pox virus infection.

The invention discloses application of AvBD-5 protein in resisting avian influenza virus infection, and belongs to the technical field of biology. A recombinant plasmid containing a coding sequence of the AvBD-5 protein is transformed into an escherichia coli expression system, IPTG is used for inducing expression of the AvBD-5 protein, the expressed AvBD-5 protein is purified, the high-concentration purified AvBD-5 protein is obtained through ultrafiltration and concentration, the protein can remarkably reduce the virus load of the H9N2 avian influenza virus in in-vivo and in-vitro experiments, and the virus load of the H9N2 avian influenza virus can be remarkably reduced. Meanwhile, the polypeptide has a prominent immunoregulation function, and can specifically inhibit the expression of TLR4 and block the activation of a TLR4 / NF-kappa B signal channel by regulating the immunologic function of red blood cells. The protein can be used as a novel immunomodulator or a drug candidate, and is used for preventing and treating H9N2 avian influenza virus infection.

The invention relates to the technical field of gene detection, and discloses a plasmid standard substance for quantitatively detecting Kaposi sarcoma-related herpes virus and a construction method thereof. A primer capable of amplifying a KSHV ORF26 target fragment containing BamH I / Xba I double restriction enzyme cutting sites is designed, and the target fragment is connected to a carrier pBluescript SK (+), so that a plasmid standard substance capable of being used for quantitatively detecting the KSHV is obtained. The plasmid standard substance can be used for rapidly and quantitatively detecting the KSHV, the detection method is convenient and rapid, the operability is high, the sensitivity is high, KSHV genes are rapidly recognized and the virus load is obtained under the conditions that the sample virus load is low and the sample is improperly stored, and a foundation is laid for early discovery and prevention of diseases. Important data can be provided for epidemiological virus traceability, pathogenicity conditions and clinical treatment.

Methods of reducing hepatitis delta virus (HDV) viral loads in a patient are provided. In some embodiments, the method comprises treating the patient with lonafarnib-ritonavir co-therapy. In some embodiments, the method further comprises treating the patient with an interferon.

This invention belongs to the field of biomedical technology, specifically disclosing a scorpion-derived polypeptide for combating influenza virus and its applications. The scorpion-derived polypeptide has the amino acid sequence shown in SEQ ID NO:1, or is a functional variant obtained by substitution, deletion, and / or addition of one or more amino acids from the same sequence, retaining its anti-influenza virus activity. The scorpion-derived polypeptide provided by this invention can significantly inhibit the proliferation of influenza A virus and substantially reduce the expression levels of viral RNA and protein within a non-cytotoxic concentration range. It also effectively reduces viral load and inflammatory factor levels in mice infected with influenza A virus, exhibiting excellent anti-influenza A virus activity and being less likely to induce viral resistance. This invention provides a novel, highly efficient, and low-toxicity bioactive molecule for influenza prevention and control, which can be applied to the development of anti-influenza drugs.

The present invention relates to use of β-glucan extracts in the immunopotentiation of an avian animal. Specifically, the present invention provides a kit, wherein the kit comprises (1) an immunopotentiator used for immunopotentiation of an avian animal, wherein the immunopotentiator comprises a β-glucan extract which is extracted from Saccharomyces cerevisiae cell wall; and (2) a virus vaccine. The present invention also provides use of a β-glucan extract which is extracted from Saccharomyces cerevisiae cell wall, in the preparation of a kit used for immunopotentiation of an avian animal and immunopotentiator. The present invention uses a β-glucan extract, which is extracted from Saccharomyces cerevisiae cell wall, for immunopotentiation of an avian animal, which can enhance lymphocyte proliferation responses and T cell responses of vaccinated animals; decrease the viral load; reduce the morbidity or mortality; produce antibodies in advance; and increase antibody production; and / or restrict the spread of the virus.

The invention is directed to methods and systems for early detection of viral diseases, and more specifically to systems and methods for early detection of viral diseases that are capable of detecting very low viral loads, such as for example and not limitation, SARS-CoV-2 loads.

The present application belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition, a preparation method and application thereof. Specifically, based on the theory of traditional Chinese veterinary medicine of'strengthening the body resistance and eliminating pathogenic factors, and treating the root and branch', aiming at the pathogenesis of 'deficiency in the root and excess in the branch' of low immunity in animals, eight kinds of medicinal materials are scientifically screened to form a traditional Chinese medicine compound with the effects of tonifying qi and nourishing blood, invigorating the spleen and kidney, dredging collaterals and eliminating dampness, and clearing heat and detoxifying. Through the verification of a cyclophosphamide-induced low immunity mouse model, the traditional Chinese medicine composition can significantly improve the mental state of the mice, restore the body weight and thymus / spleen index, repair the pathological damage of the spleen tissue, and adjust the inflammatory factor level in the serum and spleen tissue. In addition, in a Marek's disease virus infection model, the traditional Chinese medicine composition combined with the Marek's disease virus vaccine can significantly reduce the viral load in the peripheral blood, liver and spleen, and reduce the liver enlargement, hemorrhage and microscopic structure damage, showing a good immune synergistic effect.

The invention provides an attenuated pertussis CS recombinant bacterium, the CS recombinant bacterium is obtained by mutating a ninth arginine residue of an S1 subunit in a CS strain with a preservation number of CMCC 58003 into a lysine residue and mutating a 129th glutamic acid residue into a glycine residue, and the amino acid sequence of the S1 subunit of the CS recombinant bacterium is as shown in SEQ ID NO.1. The invention further provides a preparation method of the attenuated pertussis CS recombinant bacterium. The method for constructing the recombinant bacteria comprises the following steps: constructing recombinant plasmids; preparing competent cells of the wild pertussis CS strain; electrically transferring the recombinant plasmid into competent cells of the wild pertussis CS strain; respectively preparing BG sheep blood screening plates containing Amp and DOG; sequentially screening a first round and a second round of recombinant pertussis CS strains; and preparing the two-round recombinant pertussis CS strain into a competent strain, and screening twice according to the same steps to obtain the attenuated pertussis CS recombinant strain. The constructed recombinant bacteria can efficiently obtain detoxified PT, and can be applied to products for treating, detecting and preventing pertussis diseases.